BioSpace News Archive

Annexon, Inc. announced the company will present results from the ongoing ARCHER Phase 2 trial in patients with geographic atrophy at the American Society of Retina Specialists 2023 Annual Meeting taking place July 28 – August 1, 2023 in Seattle.

Kodiak Sciences Inc. announced topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate.

ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics.

Eagle Pharmaceuticals, Inc. announced that the first patient has been randomized in its multi-center adaptive, randomized, double-blind, placebo-controlled Phase 2 study designed to assess the efficacy and safety of CAL02 administered intravenously in addition to standard of care in patients with severe community-acquired bacterial pneumonia.

ImmunoBiochem Corporation announced a multi-target license and option agreement with ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, to advance novel, first-in-class ADCs.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced that it presented data on the hereditary angioedema attack journey and a patient preference study at the 2023 US HAEA National Summit in Orlando, Florida.

BD Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration 510 clearance for the updated BD Alaris™ Infusion System:.

Cara Therapeutics, Inc. today announced the Company will host a conference call and live audio webcast on Monday, August 7, 2023, at 4:30 p.m. ET to report second quarter 2023 financial results and provide a corporate update.

Replay and The University of Texas MD Anderson Cancer Center (“MD Anderson”), today announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for relapsed or refractory multiple myeloma.

Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) announces that it is presenting results of its Quality Assessment Products (“QAPs™”) for supporting the clinical use and accuracy of multiplex tests for four of the most prevalent sexually-transmitted infections (“STIs”) at the American Association of Clinical Chemistry (“AACC”) conference taking place in Anaheim, California July 23 to 27, 2023.